http://orcid.org/0000-0002-5873-9305
Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Sebastian Torke & Martin S. Weber. (2020) Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opinion on Investigational Drugs 29:10, pages 1143-1150.
Read now
Read now
Articles from other publishers (22)
Man Chen, Shuangqing Du, Yue Cheng, Xiaohong Zhu, Ying Wang, Shiqing Shu, Yuchun Men, Miao He, Huifang Wang, Zhenyu He, Ling Cai, Jie Zhu, Zhe Wu, Yuqiong Li & Ping Feng. (2024) Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study. International Immunopharmacology 126, pages 111285.
Crossref
Crossref
Ahmed Nadeem, Samiyah Alshehri, Naif O. Al-Harbi, Sheikh F. Ahmad, Norah A. Albekairi, Saleh A. Alqarni, Khaild E. Ibrahim, Ali S. Alfardan, Ali A. Alshamrani, Sami B. Bin Salman & Sabry M. Attia. (2023) Bruton’s tyrosine kinase inhibition suppresses neutrophilic inflammation and restores histone deacetylase 2 expression in myeloid and structural cells in a mixed granulocytic mouse model of asthma. International Immunopharmacology 117, pages 109920.
Crossref
Crossref
Xiangfan Yu, Simei Qiu, Dongshan Sun, Pei Guo & Quhuan Li. (2022) Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations. Molecules 27:21, pages 7451.
Crossref
Crossref
Aqu Alu, Hong Lei, Xuejiao Han, Yuquan Wei & Xiawei Wei. (2022) BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Andrea Rubbert-Roth. (2022) Combination therapies in rheumatoid arthritis—choose your partner carefully. The Lancet Rheumatology 4:6, pages e376-e377.
Crossref
Crossref
Roy Fleischmann, Alan Friedman, Edit Drescher, Atul Singhal, Gregorio Cortes-Maisonet, Thao Doan, Wenjing Lu, Zailong Wang, Ahmed Nader, William Housley, Stanley Cohen, Peter C Taylor & Ricardo Blanco. (2022) Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. The Lancet Rheumatology 4:6, pages e395-e406.
Crossref
Crossref
Ewa Robak & Tadeusz Robak. (2022) Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. Journal of Clinical Medicine 11:10, pages 2807.
Crossref
Crossref
Bruno Tasso, Andrea Spallarossa, Eleonora Russo & Chiara Brullo. (2021) The Development of BTK Inhibitors: A Five-Year Update. Molecules 26:23, pages 7411.
Crossref
Crossref
Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks & Odilia B. J. Corneth. (2021) Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. Drugs 81:14, pages 1605-1626.
Crossref
Crossref
Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo & Andrea Spallarossa. (2021) Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences 22:14, pages 7641.
Crossref
Crossref
Roy Fleischmann. (2021) The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal. The Journal of Rheumatology 48:7, pages 957-959.
Crossref
Crossref
François Chasset, Jean-Michel Dayer & Carlo Chizzolini. (2021) Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment. Frontiers in Pharmacology 12.
Crossref
Crossref
Jiamin Zheng, Jun Wu, Xiao Ding, Hong C. Shen & Ge Zou. (2021) Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 38, pages 127862.
Crossref
Crossref
H. Yesid Estupiñán, Anna Berglöf, Rula Zain & C. I. Edvard Smith. (2021) Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Anurag S. Srivastava, Soo Ko, Scott H. Watterson, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Rodney Vickery, Lorell N. Discenza, Celia J. D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Kim W. McIntyre, Shiuhang Yip, Peng Li, Dawn Sun, Dauh-Rurng Wu, Jun Dai, Chunlei Wang, Yingru Zhang, Bei Wang, Joseph Pawluczyk, James Kempson, Rulin Zhao, Xiaoping Hou, Richard Rampulla, Arvind Mathur, Michael A. Galella, Luisa Salter-Cid, Joel C. Barrish, Percy H. Carter, Aberra Fura, James R. Burke & Joseph A. Tino. (2020) Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. ACS Medicinal Chemistry Letters 11:11, pages 2195-2203.
Crossref
Crossref
Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng & Brian T. Hopkins. (2020) Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. Journal of Medicinal Chemistry 63:21, pages 12526-12541.
Crossref
Crossref
Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Rui Zhao, Joshua Galanter, Chin Lee, Julie Rae, Balazs Toth, Nandhini Ramamoorthi, Jason A. Hackney, Alberto Berman, Nemanja Damjanov, Dmytro Fedkov, Slawomir Jeka, Leslie W. Chinn, Michael J. Townsend, Alyssa M. Morimoto, Mark C. Genovese, Alberto Berman, Alejandro Porto, Amelia Granel, Cecilia Asnal, Eduardo Fabian Mysler, Gladys Alicia Testa, Jose Luis Velasco Zamora, Jose Luis Cristian Moreno, Juan Pablo Gulin, Julio Hofman, Maria Rosa Ulla, Mirtha Sabelli, Pablo Alejandro Mannucci, Pablo Jorge Maid, Ana Cláudia Cauceglia Melazzi, Antônio Scafuto Scotton, Antônio Carlos Ximenes, Elisete Funes, Emerson Alves Gimenez, Flora Maria D’Andrea Marcolino, João Francisco Marques Neto, Mauro Waldemar Keiserman, Sebastião Cézar Radominski, Sônia Maria Alvarenga Anti Loduca Lima, Thaís Rohde Pavan, Valderílio Feijó Azevedo, Aneliya Koleva, Antoaneta Toncheva, Daniela Bichovska, Delina Ivanova, Dimitar Penev, Emil Dimitrov, Mariyana Mihaylova, Nadezhda Kapandjieva, Natalia Marinova, Tanya Aleksieva, Tanya Tsvetanova, Tsvetanka Petranova, Valentina Popova, Yuliy Spasov, Carlos Enrique Toro, Carlos Ernesto Arteaga Unigarro, Edwin Jauregui, Javier Dario Marquez Hernandez, Juan Jose Jaller Raad, Patricia Julieta Velez Sanchez, Chang Keun Lee, Chang‐Hee Suh, Eun Young Lee, Sang‐Heon Lee, Seong Wook Kang, Shin‐Seok Lee, Yun Jong Lee, Beatriz Elena Zazueta Montiel, Blanca Irma Pinzon de la O, Daniel Xibille Friedmann, Francisco Rosas Lopez, Isaura Rodriguez Torres, Luis Jara Quezada, Marco Maradiaga Ceceña, Miguel Cortes Hernandez, Miguel Saavedra Salinas, Agnieszka Rapa, Agnieszka Pawtel, Agnieszka Zielinska, Anna Dudek, Anna Rychlewska‐Hanczewska, Anna Strzelecka, Artur Racewicz, Barbara Stasiuk, Katarzyna Gruszecka, Krystyna Dworak, Slawomir Jeka, Tomasz Lowenhoff, Alexey Maslyanskiy, Andrey Rebrov, Diana Krechikova, Elena Zhugrova, Evgeniya Shmidt, Galina Matsievskaya, Irina Vinogradova, Irina Ler, Larisa Eliseeva, Ludmila Savina, Marina Stanislav, Mikhail Sandin, Natalia Zyablova, Nikolay Korshunov, Nino Mosesova, Oksana Polovnikova, Olga Nesmeyanova, Ruzana Samigullina, Sergey Moiseev, Sergey Noskov, Tatiana Raskina, Tatiana Popova, Valeriy Marchenko, Aleksandar Jovanovski, Bojana Stamenkovic, Gorica Ristic, Milijanka Lazarevic, Mirjana Veselinovic, Nada Vujasinovic‐Stupar, Nemanja Damjanov, Predrag Ostojic, Andriy Yagensky, Andriy Gnylorybov, Dmytro Rekalov, Dmytroo Reshotko, Dmytro Fedkov, Georgiy Dzyak, Iurii Gasanov, Ludmila Khimion, Mykola Stanislavchuk, Natalya Prykhodko, Oleg Nadashkevych, Oleg Bortkevych, Orest Abrahamovych, Roman Yatsyshyn, Samvel Turyanytsya, Svitlana Smiyan, Vadym Vizir, Victoria Kachur, Vira Tseluyko, Vladyslav Povoroznyuk, Volodymyr Koshlia, Vyacheslav Zhdan, Yurii Lymar, Yuriy Mostovoy, Angela Hawkes, Arthur Mabaquiao, Cong‐Qiu Chu, Craig Scoville, David Wyatt, Debra Weinstein, Harris McIlwain, Jacqueline Vo, Jeffrey Poiley, Joseph Forstot, Kathryn Dao, Mark Turner, Mark Genovese, Michael Borofsky, Paul Caldron, Philip Waller, Robert Levin, Samy Metyas, Scott Stein, Sharukh Shroff, Shirley Pang, Stanley Cohen, Tauseef Syed & Vishala Chindalore. (2020)
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase
II
Trial
. Arthritis & Rheumatology 72:9, pages 1435-1446.
Crossref
Crossref
Julien Blaess, Julia Walther, Arthur Petitdemange, Jacques-Eric Gottenberg, Jean Sibilia, Laurent Arnaud & Renaud Felten. (2020) Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2095997.
Crossref
Crossref
Bin Ma, Chaomin Li, Brian T. Hopkins, Lloyd Franklin, Robbie Chen, Tamera Mack, Daniel Patience, William F. Kiesman & Erin M. O’Brien. 2020. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 3. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 3
313
337
.
Robert Pulz, Daniela Angst, Janet Dawson, Francois Gessier, Sascha Gutmann, Rene Hersperger, Alexandra Hinniger, Philipp Janser, Guido Koch, Laszlo Revesz, Anna Vulpetti, Rudolf Waelchli, Alfred Zimmerlin & Bruno Cenni. (2019) Design of Potent and Selective Covalent Inhibitors of Bruton’s Tyrosine Kinase Targeting an Inactive Conformation. ACS Medicinal Chemistry Letters 10:10, pages 1467-1472.
Crossref
Crossref
Philipp Haselmayer, Montserrat Camps, Lesley Liu-Bujalski, Ngan Nguyen, Federica Morandi, Jared Head, Alison O’Mahony, Simone C. Zimmerli, Lisa Bruns, Andrew T. Bender, Patricia Schroeder & Roland Grenningloh. (2019) Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. The Journal of Immunology 202:10, pages 2888-2906.
Crossref
Crossref
Christopher M. Harris, Sage E. Foley, Eric R. Goedken, Mark Michalak, Sara Murdock & Noel S. Wilson. (2018) Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase. SLAS Discovery 23:10, pages 1040-1050.
Crossref
Crossref